HDAC9 and neoplasm: Thus, HDAC inhibitors have the potential to counter heterogeneity in transcription and resistance by disrupting clonal gene overexpression—such as that of the c-Myc oncogene [86]—and the transcription of genes induced by regional signals in the tumor microenvironment, such as TGFβ [90,93].